RNA, U5F small nuclear 8, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU5F-8P profile across patient tissues and cancer cell-line models. RNU5F-8P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU5F-8P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, RNU5F-8P RNA expression shows 7,302 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, PRAD, and ESCA as cancer lineages where RNU5F-8P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU5F-8P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU5F-8P survival associations across molecular data types. RNU5F-8P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU5F-8P RNA expression–survival associations across cancer types. High RNU5F-8P expression shows unfavorable associations in KIRC, LUSC, LIHC, ACC, COAD and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU5F-8P RNA expression.
This table summarizes RNU5F-8P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU5F-8P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU5F-8P shows higher tumor expression in PRAD. The PRAD box plot shows higher RNU5F-8P RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p = .046).
This table shows molecular features associated with RNU5F-8P in patient tissues and cancer cell lines. In patient samples, RNU5F-8P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
